An increasing number of new anti-cancer drugs are made available each year. During the authorisation process, such new drugs usually undergo comparisons to one, but only rarely to multiple established drugs. This practice leads to a lack of comparisons...
Original Article: Neuroendocrine tumours: choosing the best treatment